A tumoural angiogenic gateway blocker, Benzophenone-1B represses the HIF-1α nuclear translocation and its target gene activation against neoplastic progression

Thirusangu, Prabhu; Vigneshwaran, V.; Ranganatha, V. Lakshmi; Avin, B.R. Vijay; Khanum, Shaukath Ara; Mahmood, Riaz; Krishnamurthy, Jayashree; Prabhakar, B.T.

doi:10.1016/j.bcp.2016.11.009

Cited by 37 publications

(17 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[22].Our experimental results show that the overexpression of IL-1RA in ESCC can reduce the expression and secretion of VEGF, and inhibiting angiogenesis in tumors. In animal experiments, CD31, a marker of vascular formation in the subcutaneous tumor-forming ， protein extracted from nude mice, was also significantly reduced in the overexpression of IL-1RA group, suggesting that IL-1RA can inhibit tumor angiogenesis and inhibit tumor progression in vivo.…”

mentioning

confidence: 65%

IL-1RA controls the development of esophageal cancer by inhibition of VEGF via PI3K/NF-κB signaling pathway

Shen

et al. 2019

Preprint

View full text Add to dashboard Cite

1.Abstract has been reported to function as tumor suppressor in a variety of tumors,but its function and mechanism in esophageal cancer remains largely unknown.Our previous studies have shown that IL-1RA is downregulated in primary esophageal cancer(EC), and this downregulation of IL-1RA is closely related to TNM staging and survival prognosis. In this study, we observed that over-expression of IL-1RA inhibits proliferation, migration, and tumor growth in esophageal cancer cells(ESCC), inhibits the expression and secretion of VEGF, and inhibits tumor angiogenesis. Further studies have shown the overexpression of IL-1RA inhibits the transmission of PI3K/NF-kappaB. Taken together, this study shows that IL-1RA can regulating the development of esophageal cancer by inhibiting VEGF expression and secretion via inhibiting PI3K/NF-kappaB signaling, and it may serve as a potential prognostic marker and therapeutic target for EC.

show abstract

mentioning

confidence: 65%

IL-1RA controls the development of esophageal cancer by inhibition of VEGF via PI3K/NF-κB signaling pathway

Shen

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…Previous studies have reported that nuclear HIF-1A expression plays an important role in biological function. Nuclear import of HIF-1A as a transcription factor is a hallmark event in HIF-1 dependant hundreds of target gene activation, such as angiogenic gene including VEGF-A, Flt-1, ang-1, MMP-2 and MMP-9 which promotes tumour angiogenesis, metastasis and clinical prognosis [29]. To date, there is no evidence to support the cytoplasmic function of HIF-1A, which may be due to the instability of cytoplasmic HIF-1A and has not been further studied.…”

Section: Discussionmentioning

confidence: 99%

“…HIF-1A expression in the cytoplasm or/and nucleus of cancer cells has been confirmed. Previous studies have shown that cytoplasm HIF-1A expression and nuclear HIF-1A expression play different roles in cancer progression [29,30]. As yet, no studies separately investigated the effect of cytoplasmic and nuclear HIF-1A expression on cancer patient progression.…”

Section: Ivyspring International Publishermentioning

confidence: 99%

Hypoxia Inducible Factor-1alpha (HIF-1A) plays different roles in Gallbladder Cancer and Normal Gallbladder Tissues

Meng

You

et al. 2021

J. Cancer

View full text Add to dashboard Cite

“…In addition to the above, benzophenone-type compounds [ 13 , 14 ] from natural products and synthesized ones have demonstrated important and valuable biological activities, with anti-inflammatory, antimicrobial, cytotoxic activities [ 15 , 16 ] and anti-angiogenesis effects [ 17 ] as examples. Nemorosone has anti-proliferative activity by targeting Akt/PKB against LAN-1 parental cell line [ 18 ] and cytotoxic activity against HeLa, eHep-2, PC-3 and U251 cancer cells [ 19 , 20 ].…”

Section: Introductionmentioning

confidence: 99%

Anti-Hyperuricemic Effect of 2-Hydroxy-4-methoxy-benzophenone-5-sulfonic Acid in Hyperuricemic Mice through XOD

Yong

et al. 2018

Molecules

View full text Add to dashboard Cite

Conventionally, benzophenone-type molecules are beneficial for alleviating the UV exposure of humans. More importantly, various compounds with this skeleton have demonstrated various biological activities. In this paper, we report the anti-hyperuricemic effect of the benzophenone compound 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid (HMS). Preliminarily, its molecular docking score and xanthine oxidase (XOD) inhibition suggested a good anti-hyperuricemic effect. Then, its anti-hyperuricemic effect, primary mechanisms and general toxicity were examined on a hyperuricemic mouse model which was established using potassium oxonate and hypoxanthine together. HMS demonstrated a remarkable anti- hyperuricemic effect which was near to that of the control drugs, showing promising perspective. General toxicity was assessed and it showed no negative effects on body weight growth and kidney function. Moreover, anti-inflammatory action was observed for HMS via spleen and thymus changes. Its anti-hyperuricemic mechanisms may be ascribed to its inhibition of XOD and its up-regulation of organic anion transporter 1 (OAT1) and down-regulation of glucose transporter 9 (GLUT9).

show abstract

A tumoural angiogenic gateway blocker, Benzophenone-1B represses the HIF-1α nuclear translocation and its target gene activation against neoplastic progression

Cited by 37 publications

References 48 publications

IL-1RA controls the development of esophageal cancer by inhibition of VEGF via PI3K/NF-κB signaling pathway

IL-1RA controls the development of esophageal cancer by inhibition of VEGF via PI3K/NF-κB signaling pathway

Hypoxia Inducible Factor-1alpha (HIF-1A) plays different roles in Gallbladder Cancer and Normal Gallbladder Tissues

Anti-Hyperuricemic Effect of 2-Hydroxy-4-methoxy-benzophenone-5-sulfonic Acid in Hyperuricemic Mice through XOD

Contact Info

Product

Resources

About